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To the editor:
Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1
Recently, Shin et al reported that the proteasomal inhibitor bortezomib inhibits the hypoxic response by stimulating the factor-inhibiting HIF-1 (FIH)-mediated repression of hypoxiainducible factor-1 (HIF-1). 1 The essence of this study is that bortezomib enhances the FIH function and the repression is dependent on asparagine 803 (N803). Both conclusions are in contradiction to previously published data, 2, 3 Shin et al suggested that this contradiction could be the consequence of a cell-type specific effect and/or the higher concentrations of bortezomib used in these previous studies.
We tested the effect of various concentrations of bortezomib on the activity of the wild type and N803A mutant Gal4 Ϫ HIF-1␣ C-terminal activation domain (CAD) in various cell lines. No inhibitory effect was observed at subnanomolar concentrations in any of 4 cell lines tested, including the HEK 293 cell line used in the Shin et al studies (data not shown). More importantly, we found that in all 4 cell lines activities of the wild type and the N803A mutant HIF-1␣ CAD constructs were strictly coregulated by bortezomib ( Figure 1 ). Both constructs were invariably inhibited by higher concentrations (Ն 10 nM), whereas 1 nM had a moderate Figure 1 . Dose-dependent effect of bortezomib on activity of the wild-type and N803A mutant HIF-1␣ CAD in various cell lines. The Gal4 Ϫ HIF-1␣ CAD constructs were cotransfected with a Gal4 reporter plasmid pFR-Luc (Stratagene, La Jolla, CA) using Effectene transfection reagent (QIAGEN, Valencia, CA). After exposure to the transfection mixture for 16 hours, the cells were trypsinized, replated, allowed to adhere for 5 hours, pretreated with bortezomib for 30 minutes, and exposed to normoxia or 0.5% O2 hypoxia (in the presence of bortezomib) for 24 hours. Activities are expressed as the ratio of luciferase activity/protein concentration in arbitrary units (AU) and each of the bars represents the mean value (Ϯ SD) from 3 independent experiments.
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Mechanistically, Shin et al concluded that the inhibitory effect of bortezomib was due to stimulation of the physical interaction between FIH and HIF-1␣ CAD. However, bortezomib treatment had no effect on cellular localization of HIF-1␣ (mainly nuclear) and FIH (cytoplasmic). 1 In our opinion, transiently enhanced interaction between 2 proteins that eventually end up in different cellular compartments cannot explain the potent inhibitory effect. Should FIH be implicated, before being released, HIF-1␣ would have to be inactivated (presumably permanently) by hydroxylation of N803. It is not clear, however, how this hydroxylation could efficiently proceed under conditions of hypoxia, the major physiologic inhibitor of FIH, without a significant up-regulation of FIH. Shin et al failed to discuss the conclusion of Birle and Hedley that FIH does not play a role in the inhibitory effect of bortezomib. 3 In addition, their statement that "demonstration that CAD activity was regulated by FIH expression or knock-down even at an O 2 tension of 1%, indicating that FIH regulates CAD even in hypoxia" was misassigned to our studies. 2 Their statement that "bortezomib inhibited HIF-1␣ more so than proteasome" cannot be justified exclusively by the absence of stabilized HIF-1␣ or CITED2 (cAMP-responsive element-binding protein [CBP]/p300-interacting transactivators with glutamic acid [E] and aspartic acid [D]-rich tail 2) in bortezomib-treated samples (bortezomib inhibits chymotrypsin-like activity of the proteasome with K i ϭ 0.6 nM). 4 Nevertheless, Shin et al speculated that the HIF-inhibitory effect of subnanomolar concentrations of bortezomib "may not be attributable to proteasome inhibition." Bortezomib is considered a highly specific inhibitor of proteasome and before being approved for clinical use, extensive screening found no other intracellular targets. 4 Although we are not clear about the underlying cause(s), the discrepancies brought up in this Letter argue against the universal appeal of the mechanism outlined by Shin et al. More work is required before the mechanism of inhibition of HIF function by bortezomib is fully understood. 
Response

Oxygen-dependent effect of bortezomib on FIH-mediated repression of HIF-1
We previously reported that bortezomib inactivates hypoxiainducible factor-1␣ (HIF-1␣) C-terminal transactivation domain (CAD) via factor-inhibiting HIF-1 (FIH). 1 Dr Kaluz and colleagues raise several issues regarding concentrations of bortezomib and the mechanism underlying FIH stimulation. We thank them for their critical comments on our paper.
Kaluz et al demonstrated that Gal4 Ϫ CAD was inactivated by bortezomib only above 10 nM. However, it should be recalled that FIH requires oxygen to hydroxylate CAD. For this reason, we used 1% oxygen to achieve CAD activation, whereas they used 0.5% oxygen. As previously reported, 1 nM bortezomib noticeably inhibited CAD in 1% oxygen, but not in 0.5% oxygen. However, 10 nM bortezomib inhibited CAD in both oxygen tensions ( Figure 1A) . FIH overexpression inhibited CAD and FIH knock-down recovered CAD repressed by 1 nM bortezomib in 1% oxygen. However, FIH overexpression failed to inhibit CAD in 0.5% oxygen. In EPO-enhancer reporter, we obtained the same results as above ( Figure 1B ). It appears that FIH requires at least 1% oxygen to inhibit CAD, and thus, FIH-mediated CAD inhibition by bortezomib cannot occur in more severe hypoxia. Then, how does 10 nM bortezomib inhibit CAD in 0.5% oxygen? Figure 1A interfered with CAD/p300 binding and was also up-regulated by bortezomib above 10 nM. 1, 2 Compared with HEK293, MCF7 was less sensitive to bortezomib because 1 nM bortezomib failed to inhibit either Gal4 Ϫ CAD or EPO-enhancer activity ( Figure 1C,D) . These results support the cell type-specific sensitivity to bortezomib even in terms of FIH activation. However, FIH showed the oxygen-dependent action in MCF7, as was found in HEK293. In addition, Kaluz et al suggested that the CAD inhibition by bortezomib is independent of FIH because bortezomib inhibited CAD(N803A) mutant. However, this was also the result obtained in 0.5% oxygen and at concentrations higher than 10 nM. In 1% oxygen, CAD(N803A) was inactivated by 10 nM bortezomib, but not by 1 nM bortezomib ( Figure 1E ).
FIH has a much higher affinity for oxygen than HIF-1␣ proline hydroxylases (PHDs), and thus retains its activity even in 1% oxygen, 3 which was also found during our study. 1 Therefore, CAD hydroxylation could be reinforced by bortezomib in 1% oxygen, and this may occur in the cytoplasm before nuclear translocation of HIF-1␣. 4 Finally, Kaluz et al mentioned that our speculation concerning CAD inactivation by subnanomolar bortezomib may not be attributable to proteasome inhibition. Despite its substantial inhibition of proteasome, 10 M MG132 failed to stimulate FIH binding to HIF-1␣. As they suggested, we also found that 1 nM bortezomib inhibited proteasome over 50%. 1 Nevertheless, it is possible that the remaining proteasome activity is sufficient to degrade proteins, which is in-line with higher concentrations of
